Skip to Main Content

Paper Details

Proteomic Resistance Biomarkers for PI3K Inhibitor in Triple Negative Breast Cancer Patient-Derived Xenograft Models.
Cancers (Basel)
8
2020
AKT, Aurora kinases, BKM120, BclXL, CBP, Caveolin, EGFR, IkappaB, IntegrinaV, KLF4, MMP9, NFKB, PDX tumors, PI3K, PI3Kp85 regulatory subunit, PTEN, Patient, RANKL, TNBC, TNBC patient-derived xenograft (PDX) models, Triple Negative Breast Cancer, Vimentin, growth factor receptors, pHER3 Y1197, patient, phosphorylated AKT, triple negative breast cancer, tumor
Author NameAffiliation
Zhanfang GuoWashington University School of Medicine
Tina PrimeauWashington University School of Medicine
Jeremy HoogWashington University School of Medicine
Sherri R DaviesWashington University School of Medicine
Li DingMcDonnell Genome Institute, Siteman Cancer Center, Washington University School of Medicine
Li DingMcDonnell Genome Institute, Siteman Cancer Center, Washington University School of Medicine
Matthew J EllisDan L. Duncan Comprehensive Cancer Center and Departments of Medicine and Molecular and Cellular Biology, Baylor College of Medicine
Shunqiang LiWashington University School of Medicine
Cynthia X MaWashington University School of Medicine
  • 1 - 9

Datasets

Release 1.2